APA (7th ed.) Citation

AA, F., SY, L., B, F., E, C., M, B., MT, R., . . . JK, C. (2026). Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials. Gynecologic oncology reports, 64, 102050. https://doi.org/10.1016/j.gore.2026.102050

Chicago Style (17th ed.) Citation

AA, Francoeur, et al. "Cost Effectiveness Analysis of Immunotherapy Regimens Currently Approved in Advanced or Recurrent Endometrial Cancer: An Analysis of the NRG-GY 018, RUBY, and DUO-E Trials." Gynecologic Oncology Reports 64 (2026): 102050. https://doi.org/10.1016/j.gore.2026.102050.

MLA (9th ed.) Citation

AA, Francoeur, et al. "Cost Effectiveness Analysis of Immunotherapy Regimens Currently Approved in Advanced or Recurrent Endometrial Cancer: An Analysis of the NRG-GY 018, RUBY, and DUO-E Trials." Gynecologic Oncology Reports, vol. 64, 2026, p. 102050, https://doi.org/10.1016/j.gore.2026.102050.